380 related articles for article (PubMed ID: 29871698)
1. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
Sadaat M; Jang S
J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
[TBL] [Abstract][Full Text] [Related]
2. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis.
Wang C; Sun W; Li Z; Wu T; Fang W
Invest New Drugs; 2023 Dec; 41(6):834-841. PubMed ID: 37897650
[TBL] [Abstract][Full Text] [Related]
4. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the
Al-Samkari H; Snyder GD; Nikiforow S; Tolaney SM; Freedman RA; Losman JA
J Med Genet; 2019 Jan; 56(1):39-42. PubMed ID: 30287596
[TBL] [Abstract][Full Text] [Related]
5. Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.
Rajapakse P; Andanamala H
World J Oncol; 2022 Apr; 13(2):49-52. PubMed ID: 35571340
[TBL] [Abstract][Full Text] [Related]
6. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy.
Holmes Z; Courtney A; Hiong A
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35948362
[TBL] [Abstract][Full Text] [Related]
7. Encephalitis Associated With Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitors: An Unfamiliar Spin-Off.
Ghous G; Shoukat HMH; Tarar ZI; Zafar MU; McGreevy JW
Cureus; 2021 Jun; 13(6):e16079. PubMed ID: 34345559
[TBL] [Abstract][Full Text] [Related]
8. Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature.
Rubio-Perez J; Rodríguez-Perez ÁR; Díaz-Blázquez M; Moreno-García V; Dómine-Gómez M
J Med Case Rep; 2022 Oct; 16(1):365. PubMed ID: 36195892
[TBL] [Abstract][Full Text] [Related]
9. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
Noseda R; Bertoli R; Müller L; Ceschi A
J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
[TBL] [Abstract][Full Text] [Related]
10. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review.
Mizuta H; Nakano E; Takahashi A; Koyama T; Namikawa K; Yamazaki N
Dermatol Ther; 2020 May; 33(3):e13321. PubMed ID: 32191382
[TBL] [Abstract][Full Text] [Related]
11. Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy.
Pacholczak-Madej R; Grela-Wojewoda A; Lompart J; Żuchowska-Vogelgesang B; Ziobro M
Prague Med Rep; 2022; 123(1):35-42. PubMed ID: 35248163
[TBL] [Abstract][Full Text] [Related]
12. Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
Machlańska A; Helbig G; Chromik K; Zapała M; Zwiernik B; Selmaj K
Mult Scler; 2021 Oct; 27(11):1803-1805. PubMed ID: 33666121
[TBL] [Abstract][Full Text] [Related]
13. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
[TBL] [Abstract][Full Text] [Related]
14. Ganglionar tuberculosis infection evolving to hemophagocytic lymphohistiocytosis after anti-programmed cell death 1 treatment for high-risk melanoma: a case report.
Costa CM; Gadotti LL; Seiwald MC; Salgues ACR; Ganem F; Nascimento ECT; Uip DE; Arrais-Rodrigues C; Munhoz RR
J Med Case Rep; 2021 Jul; 15(1):350. PubMed ID: 34233733
[TBL] [Abstract][Full Text] [Related]
15. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases.
Xu Z; Li H; Yu X; Luo J; Zhang Z
Hematology; 2024 Dec; 29(1):2340144. PubMed ID: 38606818
[TBL] [Abstract][Full Text] [Related]
16. PD-1 blockader-associated atypical hemophagocytic lymphohistiocytosis: A cautionary case report.
He L; Zhuang Y; Zhang D; Tang Z
Transfus Apher Sci; 2023 Apr; 62(2):103603. PubMed ID: 36470726
[TBL] [Abstract][Full Text] [Related]
17. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
Teachey DT; Rheingold SR; Maude SL; Zugmaier G; Barrett DM; Seif AE; Nichols KE; Suppa EK; Kalos M; Berg RA; Fitzgerald JC; Aplenc R; Gore L; Grupp SA
Blood; 2013 Jun; 121(26):5154-7. PubMed ID: 23678006
[TBL] [Abstract][Full Text] [Related]
18. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.
Kurozumi A; Takahashi H; Watanabe T; Iwasaki Y
Thorac Cancer; 2021 May; 12(10):1625-1628. PubMed ID: 33783978
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.
Kalmuk J; Puchalla J; Feng G; Giri A; Kaczmar J
Cancers Head Neck; 2020; 5():3. PubMed ID: 32025343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
